Marker Therapeutics
MRKR
26 hedge funds and large institutions have $10.9M invested in Marker Therapeutics in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 2 closing their positions.
24% more capital invested
Capital invested by funds: $8.82M → $10.9M (+$2.07M)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.24% more ownership
Funds ownership: 22.04% → 22.29% (+0.24%)
7% less funds holding
Funds holding: 28 → 26 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$94.3K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$38.8K |
| 3 |
Morgan Stanley
New York
|
+$17.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$13.6K |
| 2 |
Renaissance Technologies
New York
|
-$9.15K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3K |
| 4 |
MA
MCF Advisors
Covington,
Kentucky
|
-$2.77K |
| 5 |
JP Morgan Chase
New York
|
-$2.71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MA
26
MCF Advisors
Covington,
Kentucky
| – | -$2.77K | -609 | Closed |
|
27
UBS Group
Zurich,
Switzerland
| – | -$422 | -93 | Closed |
|
MRKR Hedge Fund Activity: Q4 2023 in Review
26 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2023, worth a combined $10.9M — up 24% from $8.82M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MRKR and 0 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Northern Trust, adding an estimated $94.3K. The largest seller was Osaic Holdings, cutting an estimated $13.6K.
- 26 institutional investors held Marker Therapeutics (MRKR) as of Q4 2023, down from 28 in Q3 2023.
- Funds reported $10.9M of Marker Therapeutics stock for Q4 2023, up 24% quarter-over-quarter.
- 0 funds opened new Marker Therapeutics positions in Q4 2023 and 2 closed out, a net change of -2 holders.
- The largest Marker Therapeutics buyer in Q4 2023 was Northern Trust, an estimated $94.3K added.
- The largest Marker Therapeutics seller in Q4 2023 was Osaic Holdings, an estimated $13.6K sold.
Based on aggregated 13F filings for Q4 2023.